COVID-19: outcomes in multiple myeloma

0 Views

07/14/23

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the impacts the COVID-19 pandemic has had on the management and treatment of multiple myeloma. An analysis of 650 patients with plasma cell disorders who were hospitalized with COVID-19 reported that age, high-risk disease status, renal disease and sub-optimal myeloma control were independent predictors of adverse outcomes with COVID-19 infection. Dr Munshi also discusses COVID-19 vaccination recommendations for patients with multiple myeloma. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.